

Ezetimibe / Atorvastatin Formulation

Version 3.7 Revision Date: 04/09/2021 SDS Number: 26475-00017 Date of last issue: 10/16/2020
Date of first issue: 10/29/2014

SECTION 1. IDENTIFICATION

Product name : Ezetimibe / Atorvastatin Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Organon & Co.
Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302
Telephone : 551-430-6000
Emergency telephone : 215-631-6999
E-mail address : EHSSTEWARD@organon.com


Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with the Hazardous Products Regulations**

Specific target organ toxicity : Category 2 (Liver, muscle)
- repeated exposure (Oral)

GHS label elements

Hazard pictograms : 

Signal Word : Warning

Hazard Statements : H373 May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
P260 Do not breathe dust.
Response:
P314 Get medical attention if you feel unwell.
Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SAFETY DATA SHEET



Ezetimibe / Atorvastatin Formulation



Version 3.7 Revision Date: 04/09/2021 SDS Number: 26475-00017 Date of last issue: 10/16/2020
Date of first issue: 10/29/2014

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Cellulose	No data available	9004-34-6	$\geq 10 - < 30$ *
Atorvastatin	No data available	134523-03-8	$\geq 10 - < 30$ *
Ezetimibe	No data available	163222-33-1	$\geq 1 - < 5$ *
Magnesium stearate	Octadecanoic acid, magnesium salt (2:1)	557-04-0	$\geq 1 - < 5$ *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May cause damage to organs through prolonged or repeated exposure if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

SAFETY DATA SHEET



Ezetimibe / Atorvastatin Formulation



Version 3.7 Revision Date: 04/09/2021 SDS Number: 26475-00017 Date of last issue: 10/16/2020
Date of first issue: 10/29/2014

- potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Fluorine compounds
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
-

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-

SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.

SAFETY DATA SHEET



Ezetimibe / Atorvastatin Formulation



Version 3.7 Revision Date: 04/09/2021 SDS Number: 26475-00017 Date of last issue: 10/16/2020
Date of first issue: 10/29/2014

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

Minimize dust generation and accumulation.

Keep container closed when not in use.

Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid :

Do not store with the following product types:

Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	CA AB OEL
		TWA (Total dust)	10 mg/m ³	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m ³	CA BC OEL
		TWAEV (total dust)	10 mg/m ³	CA QC OEL
Atorvastatin	134523-03-8	TWA	10 mg/m ³	ACGIH
		TWA	0.05 mg/m ³ (OEB 3)	Internal
Ezetimibe	163222-33-1	Wipe limit	0.5 mg/100 cm ²	Internal
		TWA	25 µg/m ³ (OEB 3)	Internal
Magnesium stearate	557-04-0	Wipe limit	250 µg/100 cm ²	Internal
		TWA	10 mg/m ³	CA AB OEL
		TWA	10 mg/m ³	CA BC OEL
		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

Engineering measures

: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

SAFETY DATA SHEET



Ezetimibe / Atorvastatin Formulation



Version 3.7 Revision Date: 04/09/2021 SDS Number: 26475-00017 Date of last issue: 10/16/2020
Date of first issue: 10/29/2014

Minimize open handling.

Personal protective equipment

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : powder
- Color : off-white
- Odor : No data available
- Odor Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : No data available
- Flash point : Not applicable
- Evaporation rate : No data available

SAFETY DATA SHEET



Ezetimibe / Atorvastatin Formulation



Version 3.7 Revision Date: 04/09/2021 SDS Number: 26475-00017 Date of last issue: 10/16/2020
Date of first issue: 10/29/2014

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : 0.01 g/l

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

Ezetimibe / Atorvastatin Formulation

Version 3.7 Revision Date: 04/09/2021 SDS Number: 26475-00017 Date of last issue: 10/16/2020
Date of first issue: 10/29/2014

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Atorvastatin:

Acute oral toxicity : LD50 (Rat, male and female): > 5,000 mg/kg
LD50 (Mouse, male and female): > 5,000 mg/kg

Ezetimibe:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
LD50 (Mouse): > 5,000 mg/kg
LD50 (Dog): > 3,000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 2,000 mg/kg
Application Route: Intraperitoneal
LD50 (Mouse): > 1,000 - < 2,000 mg/kg
Application Route: Intraperitoneal

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Ezetimibe / Atorvastatin Formulation

Version 3.7 Revision Date: 04/09/2021 SDS Number: 26475-00017 Date of last issue: 10/16/2020
Date of first issue: 10/29/2014

Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:**Atorvastatin:**

Species : Rabbit
Result : No skin irritation

Ezetimibe:

Species : Rabbit
Result : No skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Atorvastatin:**

Species : Rabbit
Result : No eye irritation
Method : Draize Test

Ezetimibe:

Species : Rabbit
Result : No eye irritation

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Atorvastatin:**

Test Type : Maximization Test

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.7	04/09/2021	26475-00017	Date of first issue: 10/29/2014

Routes of exposure : Skin contact
 Species : Guinea pig
 Result : negative

Ezetimibe:

Test Type : Maximization Test
 Species : Guinea pig
 Result : negative

Magnesium stearate:

Test Type : Maximization Test
 Routes of exposure : Skin contact
 Species : Guinea pig
 Method : OECD Test Guideline 406
 Result : negative
 Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
 Result: negative

Test Type: In vitro mammalian cell gene mutation test
 Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
 Species: Mouse
 Application Route: Ingestion
 Result: negative

Atorvastatin:

Genotoxicity in vitro : Test Type: reverse mutation assay
 Test system: Salmonella typhimurium
 Result: negative

Test Type: reverse mutation assay
 Test system: Escherichia coli
 Result: negative

Test Type: In vitro mammalian cell gene mutation test
 Test system: Chinese hamster lung cells
 Result: negative

Test Type: sister chromatid exchange assay
 Test system: Chinese hamster lung cells
 Result: negative

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.7	04/09/2021	26475-00017	Date of first issue: 10/29/2014

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Ezetimibe:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Metabolic activation: with and without metabolic activation
Result: negative

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Atorvastatin:

Species : Mouse, male and female
Application Route : oral (gavage)
Exposure time : 2 Years
NOAEL : 200 mg/kg body weight
LOAEL : 400 mg/kg body weight

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.7	04/09/2021	26475-00017	Date of first issue: 10/29/2014

Result	: negative
Target Organs	: Liver
Species	: Rat, female
Application Route	: oral (gavage)
Exposure time	: 2 Years
LOAEL	: 100 mg/kg body weight
Target Organs	: Musculo-skeletal system

Ezetimibe:

Species	: Rat, female
Application Route	: oral (feed)
Exposure time	: 104 weeks
Result	: negative

Species	: Rat, male
Application Route	: oral (feed)
Exposure time	: 104 weeks
Result	: negative

Species	: Mouse
Application Route	: oral (feed)
Exposure time	: 104 weeks
Result	: negative

Reproductive toxicity

Not classified based on available information.

Components:**Cellulose:**

Effects on fertility	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
----------------------	---

Effects on fetal development	: Test Type: Fertility/early embryonic development Species: Rat Application Route: Ingestion Result: negative
------------------------------	--

Atorvastatin:

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat, female Fertility: NOAEL: 225 mg/kg body weight Result: No effects on fertility.
----------------------	---

	: Test Type: Fertility/early embryonic development Species: Rat, male Fertility: NOAEL: 175 mg/kg body weight Result: No effects on fertility.
--	---

Effects on fetal development	: Species: Rat, female
------------------------------	------------------------

Ezetimibe / Atorvastatin Formulation

Version 3.7 Revision Date: 04/09/2021 SDS Number: 26475-00017 Date of last issue: 10/16/2020
Date of first issue: 10/29/2014

Developmental Toxicity: NOAEL: 20 mg/kg body weight
Result: No teratogenic effects., Embryo-fetal toxicity.
Remarks: Maternal toxicity observed.

Species: Rabbit, female
Application Route: Oral
Developmental Toxicity: NOAEL: 100 mg/kg body weight
Result: No embryo-fetal toxicity.

Ezetimibe:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male and female
Fertility: NOAEL: > 1,000 mg/kg body weight
Result: No effects on fertility., No fetotoxicity.

Effects on fetal development : Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
Result: No adverse effects.

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight
Result: No adverse effects.

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.

Components:**Atorvastatin:**

Routes of exposure : Ingestion

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.7	04/09/2021	26475-00017	Date of first issue: 10/29/2014

Target Organs : Liver, muscle
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Cellulose:**

Species : Rat
 NOAEL : >= 9,000 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Atorvastatin:

Species : Rat, male and female
 LOAEL : 70 mg/kg
 Application Route : oral (gavage)
 Exposure time : 52 Weeks
 Target Organs : Liver

Species : Dog
 LOAEL : 10 mg/kg
 Application Route : oral (gavage)
 Exposure time : 104 Weeks
 Target Organs : Liver

Ezetimibe:

Species : Dog
 NOAEL : 1,000 mg/kg
 Application Route : Oral
 Exposure time : 90 d
 Remarks : No significant adverse effects were reported

Species : Rat
 NOAEL : 1,500 mg/kg
 Application Route : Oral
 Exposure time : 90 d
 Remarks : No significant adverse effects were reported

Species : Mouse
 NOAEL : 500 mg/kg
 Application Route : Oral
 Exposure time : 90 d
 Remarks : No significant adverse effects were reported

Species : Dog
 NOAEL : 300 mg/kg
 Application Route : Oral
 Exposure time : 1 y
 Remarks : No significant adverse effects were reported

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.7	04/09/2021	26475-00017	Date of first issue: 10/29/2014

Magnesium stearate:

Species	:	Rat
NOAEL	:	> 100 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Remarks	:	Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Components:**Ezetimibe:**

Not applicable

Experience with human exposure**Components:****Atorvastatin:**

Ingestion	:	Symptoms: muscle pain, Fatigue, stomach discomfort, Abdominal pain, constipation, flatulence, liver function change
-----------	---	---

Ezetimibe:

Ingestion	:	Symptoms: Headache, Nausea, Vomiting, Diarrhea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain
-----------	---	---

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish	:	LC50 (<i>Oryzias latipes</i> (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	---	--

Atorvastatin:

Toxicity to fish	:	LC50 (<i>Pimephales promelas</i> (fathead minnow)): > 92 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
------------------	---	--

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (<i>Daphnia magna</i> (Water flea)): 200 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
---	---	---

Toxicity to algae/aquatic plants	:	EC50 (<i>Pseudokirchneriella subcapitata</i> (green algae)): 108 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
----------------------------------	---	--

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.7	04/09/2021	26475-00017	Date of first issue: 10/29/2014

- NOEC (*Pseudokirchneriella subcapitata* (green algae)): 14 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
- Toxicity to fish (Chronic toxicity) : NOEC (*Pimephales promelas* (fathead minnow)): 0.49 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Daphnia magna* (Water flea)): 0.2 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
- Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
- Ezetimibe:**
- Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 0.125 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility.
- Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 4 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.
- Toxicity to algae/aquatic plants : EC50 (*Pseudokirchneriella subcapitata* (green algae)): > 0.317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.
- NOEC (*Pseudokirchneriella subcapitata* (green algae)): 0.317 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.
- Toxicity to fish (Chronic toxicity) : NOEC (*Pimephales promelas* (fathead minnow)): 0.051 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210
- NOEC (*Cyprinodon variegatus* (sheepshead minnow)): 4 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility.
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Daphnia magna* (Water flea)): 0.282 mg/l
Exposure time: 21 d
Remarks: No toxicity at the limit of solubility.
- Toxicity to microorganisms : EC50: > 4.4 mg/l
Exposure time: 3 h

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.7	04/09/2021	26475-00017	Date of first issue: 10/29/2014

Test Type: Respiration inhibition
 Method: OECD Test Guideline 209
 Remarks: No toxicity at the limit of solubility.

NOEC: 4.4 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition
 Method: OECD Test Guideline 209
 Remarks: No toxicity at the limit of solubility.

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
 Exposure time: 48 h
 Method: DIN 38412
 Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
 Exposure time: 47 h
 Test substance: Water Accommodated Fraction
 Method: Directive 67/548/EEC, Annex V, C.2.
 Remarks: Based on data from similar materials
 No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials
 No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
 Exposure time: 16 h
 Test substance: Water Accommodated Fraction
 Remarks: Based on data from similar materials

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Atorvastatin:

Biodegradability : Result: Not readily biodegradable.
 Biodegradation: 7.7 %

SAFETY DATA SHEET



Ezetimibe / Atorvastatin Formulation



Version 3.7 Revision Date: 04/09/2021 SDS Number: 26475-00017 Date of last issue: 10/16/2020
Date of first issue: 10/29/2014

Exposure time: 28 d
Method: OECD Test Guideline 314

Ezetimibe:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 6.8 %
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4.5 d)
Method: OECD Test Guideline 111

Magnesium stearate:

Biodegradability : Result: Not biodegradable.
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Atorvastatin:

Partition coefficient: n-octanol/water : log Pow: 1.62

Ezetimibe:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 173
Exposure time: 97 d
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.36

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

Atorvastatin:

Distribution among environmental compartments : log Koc: 2.84

Ezetimibe:

Distribution among environmental compartments : log Koc: 4.35
Method: OECD Test Guideline 106

Other adverse effects

No data available

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.7	04/09/2021	26475-00017	Date of first issue: 10/29/2014

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.
 Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
 If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3077
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)
 Class : 9
 Packing group : III
 Labels : 9

IATA-DGR

UN/ID No. : UN 3077
 Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Ezetimibe, Atorvastatin)
 Class : 9
 Packing group : III
 Labels : Miscellaneous
 Packing instruction (cargo aircraft) : 956
 Packing instruction (passenger aircraft) : 956
 Environmentally hazardous : yes

IMDG-Code

UN number : UN 3077
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)
 Class : 9
 Packing group : III
 Labels : 9
 EmS Code : F-A, S-F
 Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**TDG**

UN number : UN 3077
 Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Ezetimibe, Atorvastatin)
 Class : 9

Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.7	04/09/2021	26475-00017	Date of first issue: 10/29/2014

Packing group	:	III
Labels	:	9
ERG Code	:	171
Marine pollutant	:	yes(Ezetimibe, Atorvastatin)

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION**The ingredients of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION**Full text of other abbreviations**

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	:	Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	:	Canada. British Columbia OEL
CA QC OEL	:	Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA	:	8-hour, time-weighted average
CA AB OEL / TWA	:	8-hour Occupational exposure limit
CA BC OEL / TWA	:	8-hour time weighted average
CA QC OEL / TWA EV	:	Time-weighted average exposure value

AiIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect

SAFETY DATA SHEET



Ezetimibe / Atorvastatin Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 10/16/2020
3.7	04/09/2021	26475-00017	Date of first issue: 10/29/2014

Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/09/2021
Date format : mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8